Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Seeds Investor LLC

Seeds Investor LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 19.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,796 shares of the life sciences company’s stock after purchasing an additional 447 shares during the quarter. Seeds Investor LLC’s holdings in Illumina were worth $374,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in Illumina during the 4th quarter valued at about $32,000. Assetmark Inc. increased its stake in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina in the fourth quarter worth approximately $48,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ILMN. Piper Sandler lifted their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Stephens reissued an “overweight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. Royal Bank of Canada reduced their target price on Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, April 8th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, Morgan Stanley reduced their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $138.70.

Illumina Price Performance

NASDAQ:ILMN opened at $74.78 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a 50-day moving average of $88.58 and a 200-day moving average of $122.25. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a market capitalization of $11.85 billion, a price-to-earnings ratio of -9.74, a PEG ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.